Novo Nordisk A/S secured UK approval for its Wegovy pill, marking a significant milestone in expanding obesity treatment options. The oral medication joins the injectable version already available, giving patients an alternative delivery method that could appeal to those hesitant about needles.

The pill formulation addresses a key barrier to treatment adoption: injection aversion. Many patients avoid injectable weight-loss drugs despite their effectiveness, limiting market penetration for pharmaceutical companies developing obesity therapies.

For Novo Nordisk, this approval broadens the addressable market for Wegovy beyond current injectable users. The company already markets the semaglutide injection for diabetes as Ozempic and for obesity as Wegovy, but the pill version could capture patients who previously declined treatment.

UK regulators cleared the oral version for obesity treatment, signaling confidence in the medication's safety and efficacy profile. This regulatory nod may influence approval timelines in other markets where Novo Nordisk seeks to commercialize the pill form.